<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293150</url>
  </required_header>
  <id_info>
    <org_study_id>6242</org_study_id>
    <nct_id>NCT00293150</nct_id>
  </id_info>
  <brief_title>Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure</brief_title>
  <acronym>PREDICT</acronym>
  <official_title>Determine the Effectiveness of Eplerenone in Reversing Diastolic Dysfunction, Improving Endothelial Function, and Suppressing Natriuretic Peptides and Collagen Turnover in Patients With Diastolic Heart Failure ( PREDICT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principle aim is to determine the efficacy of eplerenone in patients with diastolic heart&#xD;
      failure to reverse cardiac remodeling and to improve diastolic function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a single center, double-blind, randomized, parallel group trial enrolling a&#xD;
      minimum of 80 patients designed to determine the efficacy of eplerenone in subjects with&#xD;
      diastolic heart failure. Prior to administration of study medication, a medical history,&#xD;
      physical exam, blood draw, electrocardiogram, 2D echocardiogram, and cardiomyopathy&#xD;
      questionnaire will be performed. Subjects will then be randomized to receive either&#xD;
      eplerenone 25 mg once daily or placebo for 2 weeks. At the Week 2 visit all patients will be&#xD;
      titrated up to the next dose (50 mg eplerenone once daily or placebo). Each study arm will&#xD;
      have 40 subjects who will participate for 9 months. Follow-up assessments will be completed&#xD;
      at 1 week, 2 weeks, 1 month, 3 months, 6 months, and 9 months.&#xD;
&#xD;
      Starting at the Month 1 visit, any subjects with uncontrolled blood pressure will be&#xD;
      administered add-on therapy of HCTZ (starting dose of 12.5 mg daily, that may titrate up to&#xD;
      25 mg daily) and/or amlodipine (starting dose at 5 mg daily, that may titrate up to 10 mg&#xD;
      daily). Any subject who receives add-on therapy must have their blood pressure checked within&#xD;
      2 weeks. Uncontrolled blood pressure may be treated by either increasing the add-on therapy&#xD;
      dose or increasing the add-on therapy regimen to include both add-on drugs. Changes in add-on&#xD;
      therapy require blood pressure checks within 2 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of eligible patients&#xD;
  </why_stopped>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double Blind placebo vs eplerenone</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of eplerenone</measure>
    <time_frame>9 months</time_frame>
    <description>Improved diastolic function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of change</measure>
    <time_frame>9 months</time_frame>
    <description>degree of changes in natriuretic peptide production, endothelial function and collagen turnover</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Diastolic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eplerenone 25mg daily for 2 weeks Titrated to Eplerenone 50mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dosed daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inspra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must meet all of the following inclusion criteria to be eligible for enrollment&#xD;
        into the study:&#xD;
&#xD;
          1. Male or non-pregnant female (if female, either post-menopausal, or if of child-bearing&#xD;
             potential, using adequate contraception e.g. hormonal or barrier methods, or&#xD;
             surgically sterile, and not lactating)&#xD;
&#xD;
          2. Age &gt;/= 18 years of age&#xD;
&#xD;
          3. Present or prior history of symptoms of heart failure (dyspnea, fatigue) consistent&#xD;
             with diagnosis of diastolic heart failure, following optimized medical therapy&#xD;
             including blood pressure control with ACE inhibitors and/or beta-blockers for 2 weeks&#xD;
             or over.&#xD;
&#xD;
          4. Echocardiographic evidence of preserved left ventricular systolic function (LVEF &gt;/=&#xD;
             45%) and evidence of diastolic dysfunction (by transmitral inflow, pulmonary venous&#xD;
             flow, color M-mode and/or tissue Doppler).&#xD;
&#xD;
          5. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any of the following will exclude a patient from study enrollment:&#xD;
&#xD;
          1. Unwilling to participate for the 9-month duration of the study&#xD;
&#xD;
          2. Significant primary valvular, pulmonary or congenital cardiac disease believed to be&#xD;
             the cause of dyspnea&#xD;
&#xD;
          3. Life expectancy or planned cardiac transplantation &lt;9 months&#xD;
&#xD;
          4. History of hypertrophic obstructive cardiomyopathy&#xD;
&#xD;
          5. Unstable angina or ischemia requiring revascularization&#xD;
&#xD;
          6. Renal insufficiency (Cr &gt;2.0 mg/dL in males and &gt;1.8 mg/dl in females, or modified&#xD;
             Cockcroft-Gault estimate of creatinine clearance &lt;30 mL/min) at enrollment&#xD;
&#xD;
          7. Known hypersensitivity to spironolactone or eplerenone&#xD;
&#xD;
          8. Decompensated heart failure or clinical evidence of instability at the time of&#xD;
             enrollment 9 History of hyperkalemia (&gt;6.0 mg/dL) with spironolactone&#xD;
&#xD;
        10. Use of spironolactone or amiloride within 30 days 11. Poorly controlled seating blood&#xD;
        pressure at the time of drug initiation:&#xD;
&#xD;
          -  Systolic blood pressure &gt;160 mmHg; and/or&#xD;
&#xD;
          -  Diastolic blood pressure &gt;100 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diastolic heart failure</keyword>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

